Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Common Equity (2019 - 2025)

Historic Common Equity for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $1.0 billion.

  • CureVac's Common Equity rose 2797.45% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 2797.45%. This contributed to the annual value of $744.4 million for FY2024, which is 3383.59% up from last year.
  • CureVac's Common Equity amounted to $1.0 billion in Q3 2025, which was up 2797.45% from $663.7 million recorded in Q2 2025.
  • CureVac's Common Equity's 5-year high stood at $1.0 billion during Q3 2025, with a 5-year trough of $405.5 million in Q2 2024.
  • Over the past 5 years, CureVac's median Common Equity value was $693.5 million (recorded in 2023), while the average stood at $704.9 million.
  • Per our database at Business Quant, CureVac's Common Equity surged by 9210026.66% in 2021 and then plummeted by 4262.8% in 2024.
  • CureVac's Common Equity (Quarter) stood at $787.6 million in 2021, then plummeted by 30.92% to $544.0 million in 2022, then increased by 2.23% to $556.2 million in 2023, then skyrocketed by 33.84% to $744.4 million in 2024, then skyrocketed by 36.83% to $1.0 billion in 2025.
  • Its Common Equity stands at $1.0 billion for Q3 2025, versus $663.7 million for Q2 2025 and $680.2 million for Q1 2025.